Researchers published a pan-cancer patient-derived organoid (PDO) platform designed for precision oncology modeling and therapeutic vulnerability screening. In Science Advances, the team described 220 PDOs generated from 191 patients across 15 cancer types, reporting high fidelity to parent tumors across histopathology, driver mutations, and gene expression signatures. The platform maintained stability over extended culture, with the study citing 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Clonality analyses indicated that most dominant tumor clones were preserved, supporting reproducible long-term preclinical testing. To demonstrate utility, the researchers tested a PARP inhibitor, talazoparib, in organoids from patients who had been deemed ineligible for PARP inhibitors by standard clinical criteria. They found that 58% of those organoids showed substantial sensitivity, suggesting current decision rules may exclude patients who could benefit.